PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Price to Sales Ratio (P/S) on December 30, 2024: 274,454,689,816,176.00

PainReform Ltd. Price to Sales Ratio (P/S) is 274,454,689,816,176.00 on December 30, 2024, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

PainReform Ltd. 52-week high Price to Sales Ratio (P/S) is 1,600,526,183,194,890.00 on December 13, 2024, which is 483.17% above the current Price to Sales Ratio (P/S).
PainReform Ltd. 52-week low Price to Sales Ratio (P/S) is 7,671,417,401.78 on August 08, 2024, which is -100.00% below the current Price to Sales Ratio (P/S).
PainReform Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 31,189,354,989,980.91.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: PRFX

PainReform Ltd.

CEO	Dr. Ehud Geller Ph.D.
IPO Date	Sept. 1, 2020
Location	Israel
Headquarters	65 Yigal Alon Street
Employees	7
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Key trends

Past 5 years